WASHINGTON (FNS) -- Two advisory committees to the Food and Drug Administration have postponed a review of whether acyclovir should be switched from prescription to over-the-counter for treating genital herpes. The committees were scheduled to meet on July 28. However, acyclovir's manufacturer, Burroughs Wellcome, Research Triangle Park, N.C., has requested more time to submit data. Once the advisory committees make their recommendation, it's up to the FDA to accept or reject it. If FDA ...

REGISTER TO VIEW THIS ARTICLE - Register for a Free Account

WhyRegisterfor FREE?

Registering for content on Supermarket News will give youINSTANTaccess to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’sFREE, easy and quick. What are you waiting for!In addition you will also receive a complimentary copy of SN's salary survey sent to you by email.

Click here to read the FAQ page if you have any questions (opens in a new window)

Attention Paid Print Subscribers: While you have already been grantedfreeaccess to SNwe ask that youregister now.We promise it will only take a few minutes! Or visit your profile and add your print magazine account number and zip code.

Already registered? here.